Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer.

Q3 Medicine

Iranian Journal of Pathology Pub Date : 2024-01-01 Epub Date: 2023-12-29 DOI:10.30699/IJP.2023.2002772.3118

Bita Eslami, Sadaf Alipour, Farzaneh Golfam, Behnaz Jahabnin, Ramesh Omranipour

{"title":"Effective Ki-67 Reduction by Pre-Surgery Short-Term Administration of Letrozole in (Hormone-Positive) Breast Cancer.","authors":"Bita Eslami, Sadaf Alipour, Farzaneh Golfam, Behnaz Jahabnin, Ramesh Omranipour","doi":"10.30699/IJP.2023.2002772.3118","DOIUrl":null,"url":null,"abstract":"Background & objective: Antigen Ki-67 (histone-based nuclear protein) is a static marker of tumor cell proliferation and growth and is commonly measured to indicate the effect of treatment in breast cancer patients. This single-arm trial study aimed to evaluate the effect of short-term endocrine therapy (letrozole) on Ki-67 levels in menopausal women with early hormone-positive breast cancer who were referred to two university hospitals.Methods: Patients with a pre-treatment Ki67 of 5% or less were excluded from the study. Participants (n=25) received oral letrozole (2.5 mg daily) seven days before surgery. Ki-67% on both biopsies and the surgical specimens were measured and compared.Results and conclusion: The mean age of patients was 62±9.4 (48-83 years). Our result indicated that pre-surgery consumption of letrozole for hormone-positive breast cancer can significantly decrease the of Ki-67 labeling index (23.24±9.74 vs. 16.92±9.55, P=0.001 by paired t-test), with no drug-related adverse events.","PeriodicalId":38900,"journal":{"name":"Iranian Journal of Pathology","volume":"19 1","pages":"103-106"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30699/IJP.2023.2002772.3118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background & objective: Antigen Ki-67 (histone-based nuclear protein) is a static marker of tumor cell proliferation and growth and is commonly measured to indicate the effect of treatment in breast cancer patients. This single-arm trial study aimed to evaluate the effect of short-term endocrine therapy (letrozole) on Ki-67 levels in menopausal women with early hormone-positive breast cancer who were referred to two university hospitals.

Methods: Patients with a pre-treatment Ki67 of 5% or less were excluded from the study. Participants (n=25) received oral letrozole (2.5 mg daily) seven days before surgery. Ki-67% on both biopsies and the surgical specimens were measured and compared.

Results and conclusion: The mean age of patients was 62±9.4 (48-83 years). Our result indicated that pre-surgery consumption of letrozole for hormone-positive breast cancer can significantly decrease the of Ki-67 labeling index (23.24±9.74 vs. 16.92±9.55, P=0.001 by paired t-test), with no drug-related adverse events.

查看原文本刊更多论文

激素阳性）乳腺癌患者手术前短期服用来曲唑可有效降低 Ki-67

背景与目的：抗原Ki-67（基于组蛋白的核蛋白）是肿瘤细胞增殖和生长的静态标记物，通常通过测定Ki-67来显示乳腺癌患者的治疗效果。这项单臂试验研究旨在评估短期内分泌治疗（来曲唑）对两家大学医院转诊的早期激素阳性乳腺癌绝经期女性患者 Ki-67 水平的影响：研究排除了治疗前 Ki67 为 5%或以下的患者。参与者（25 人）在手术前七天口服来曲唑（每天 2.5 毫克）。对活检和手术标本的Ki-67%进行测量和比较：患者的平均年龄为 62±9.4（48-83 岁）。我们的研究结果表明，激素阳性乳腺癌患者手术前服用来曲唑可显著降低Ki-67标记指数（23.24±9.74 vs. 16.92±9.55，配对t检验，P=0.001），且无药物相关不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊